Diabetes
Improved glycaemic control with fixed-ratio combination of insulin degludec and liraglutide
Source: Image Point Fr / Shutterstock.com
The DUAL trial found that rates of hypoglycaemia were lowest with liraglutide, highest with insulin degludec and intermediate with IDegLira
Basal insulin and glucagon-like peptide (GLP)-1 receptor agonists are individually effective for controlling blood glucose in patients with diabetes but are also associated with unwanted side effects.
A new fixed-ratio combination of insulin degludec, a basal insulin analogue, plus liraglutide, a GLP-1 analogue (IDegLira), has demonstrated better control of blood glucose than either drug given alone, and with no increase in hypoglycaemia.
Findings from the DUAL trial, reported in The Lancet Diabetes & Endocrinology (online, 2 September 2014), show that patients who took IDegLira (Xultophy) for 26 weeks experienced a significantly greater mean reduction in HbA1c (–1.9%) than patients taking either insulin degludec (–1.4%) or liraglutide (–1.3%)[1].
Rates of hypoglycaemia were lowest with liraglutide, highest with insulin degludec and intermediate with IDegLira.
IDegLira, a single, once-daily injectable, is expected to be authorised for use in Europe within months.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066433
Recommended from Pharmaceutical Press
- Previous
- Next
Palliative Care Formulary (PCF7)
Palliative Care Formulary is a comprehensive combination of independent information about drugs used in palliative care.
£59.95Buy now
Print 
PDF
Have your say
For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.